Sight Sciences to Present at Two Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at two upcoming conferences. * Stifel 2026 Healthcare Conference in New York, NY on Wednesday, November 11, 2026, at 7:00 am PT / 10:00 am ET. * Piper Sandler 38(th) Annual Healthcare Conference in New York, NY on Wednesday, December 2, 2026, at 12:00 pm PT / 3:00 pm ET. Interested parties may access a live and archived webcast of the fireside chats on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.

About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI(®) (link) Surgical System is an implant-free, minimally invasive glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION(®) (link) Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare(®) (link) System is 510(k) cleared in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.